-
1Academic Journal
Συγγραφείς: F. Worden, O. Rajkovic-Hooley, N. Reynolds, G. Milligan, J. Zhang
Πηγή: Опухоли головы и шеи, Vol 15, Iss 2, Pp 26-33 (2025)
Θεματικοί όροι: дифференцированный рак щитовидной железы, радиойодрефрактерность, ленватиниб, эффективность препарата в реальной клинической практике, анализ историй болезни, соединенные штаты америки, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Περιγραφή αρχείου: electronic resource
Relation: https://ogsh.abvpress.ru/jour/article/view/1068; https://doaj.org/toc/2222-1468; https://doaj.org/toc/2411-4634
Σύνδεσμος πρόσβασης: https://doaj.org/article/13e795881b584176942973349d347b1b
-
2Academic Journal
Συγγραφείς: Borodavina E.V., Shurinov A.Y., Krylov V.V.
Πηγή: Head and Neck Tumors; Vol 15, No 1 (2025); 40-46 ; Опухоли головы и шеи; Vol 15, No 1 (2025); 40-46 ; 2411-4634 ; 2222-1468
Θεματικοί όροι: progressive metastatic radioiodine refractory differentiated thyroid cancer, progression, thyroglobulin, Response evaluation criteria in solid tumors, targeted therapy, lenvatinib, response to treatment, прогрессирующий метастатический радиойодрефрактерный дифференцированный рак щитовидной железы, прогрессирование, тиреоглобулин, критерии оценки ответа солидных опухолей, таргетная терапия, ленватиниб, ответ на лечение
Περιγραφή αρχείου: application/pdf
Relation: https://ogsh.abvpress.ru/jour/article/view/1041/659; https://ogsh.abvpress.ru/jour/article/view/1041
-
3Academic Journal
Συγγραφείς: E. V. Borodavina, S. I. Kutukova, A. Yu. Shurinov, V. V. Krylov, Е. В. Бородавина, С. И. Кутукова, А. Ю. Шуринов, В. В. Крылов
Συνεισφορές: The work was prepared with the financial support of the Eisai company., Работа подготовлена при финансовой поддержке ООО «Эйсай».
Πηγή: Head and Neck Tumors (HNT); Том 14, № 4 (2024); 42-50 ; Опухоли головы и шеи; Том 14, № 4 (2024); 42-50 ; 2411-4634 ; 2222-1468
Θεματικοί όροι: терапевтические каникулы, radioiodine-refractory differentiated thyroid cancer, adverse events, progression-free survival, overall survival, drug holidays, радиойодрефрактерный дифференцированный рак щитовидной железы, нежелательные явления, выживаемость без прогрессирования, общая выживаемость
Περιγραφή αρχείου: application/pdf
Relation: https://ogsh.abvpress.ru/jour/article/view/1023/650; Pacini F., Ito Y., Luster M. et al. Radioactive iodine-refractory differentiated thyroid cancer: Unmet needs and future directions. Exp Rev Endocrinol Metab 2012;7(5):541–54. DOI:10.1586/eem.12.36; Xing M., Haugen B.R., Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet 2013;381(9871):1058–69. DOI:10.1016/S0140-6736(13)60109-9; Cabanillas M.E., Takahashi S. Лечение нежелательных явлений, ассоциированных с приемом ленватиниба, у пациентов с радиойодрефрактерным дифференцированным раком щитовидной железы. Опухоли головы и шеи 2019;9(4):49–61. DOI:10.17650/2222-1468-2019-9-4-49-61; Durante C., Haddy N., Baudin E. et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006;91(8):2892–9. DOI:10.1210/jc.2005-2838; Schlumberger M., Tahara M., Wirth L.J. et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015;372(7):621–30. DOI:10.1056/NEJMoa1406470; Gianoukakis A.G., Dutcus C.E., Batty N. et al. Prolonged duration of response in lenvatinib responders with thyroid cancer. Endocr Relat Cancer 2018;25(6):699–704. DOI:10.1530/ERC-18-0049; Бородавина Е.В., Исаев П.А., Шуринов А.Ю. и др. Эффективность и переносимость ленватиниба при радиойодрезистентном дифференцированном раке щитовидной железы по результатам многоцентрового наблюдательного исследования в Российской Федерации. Опухоли головы и шеи 2020;10(1):65–72. DOI:10.17650/2222-1468-2020-10-1-65-72; Locati L.D., Piovesan A., Durante C. et al. Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy. Eur J Cancer 2019;118:35–40. DOI:10.1016/j.ejca.2019.05.031; Takahashi S., Tahara M., Ito K. et al. Safety and effectiveness of lenvatinib in 594 patients with unresectable thyroid cancer in an all-case post-marketing observational study in Japan. Adv Ther 2020;37(9):3850–62. DOI:10.1007/s12325-020-01433-8; Kish J.K., Chatterjee D., Wan Y. et al. Lenvatinib and subsequent therapy for radioactive iodine-refractory differentiated thyroid cancer: a real-world study of clinical effectiveness in the United States. Adv Ther 2020;37(6):2841–52. DOI:10.1007/s12325-020-01362-6; Song E., Kim M., Kim E.Y. et al. Lenvatinib for radioactive iodine-refractory differentiated thyroid carcinoma and candidate biomarkers associated with survival: a multicenter study in Korea. Thyroid 2020;30(5):732–8. DOI:10.1089/thy.2019.0476; Румянцев П.О., Бородавина Е.В., Кутукова С.И., Васильева Е.Б. Персонализированная терапия ленватинибом прогрессирующего радиойодрефрактерного дифференцированного рака щитовидной железы в реальной клинической практике. Опухоли головы и шеи 2021;11(3):47–55. DOI:10.17650/2222-1468-2021-11-3-47-55; Matsuyama C., Enokida T., Ueda Y. et al. Planned drug holidays during treatment with lenvatinib for radioiodine-refractory differentiated thyroid cancer: a retrospective study. Front Oncol 2023;13:1139659. DOI:10.3389/fonc.2023.1139659; Tahara M., Takami H., Ito Y. et al. A prospective cohort study exploring the effect of lenvatinib planned drug holidays in treatment of differentiated thyroid cancer. Thyroid 2024;34(5):566–74. DOI:10.1089/thy.2023.0553; Mikoshiba T., Sekimizu M., Kono T. et al. Utility and optimal management of planned drug holidays during lenvatinib treatment in patients with unresectable differentiated thyroid cancer: a real-world multi-center study. Endocrine 2024;85(2):777–85. DOI:10.1007/s12020-024-03744-0; Felicetti F., Nervo A., Piovesan A. et al. Tyrosine kinase inhibitors rechallenge in solid tumors: a review of literature and a case description with lenvatinib in thyroid cancer. Expert Rev Anticancer Ther 2017;17(12):1093–8. DOI:10.1080/14737140.2017.1390432; Marotta V., Colao A., Faggiano A. Complete disappearance of liver metastases in a patient with iodine-refractory differentiated thyroid cancer subjected to sorafenib re-challenge. Endocrine 2015;50(3):824–5. DOI:10.1007/s12020-015-0570-5; Takinami M., Yokota T. Rechallenge with lenvatinib after refractoriness to initial lenvatinib followed by sorafenib in a patient with metastatic papillary thyroid carcinoma. Case Rep Oncol 2020;13(2):522–7. DOI:10.1159/000507344; Yokota T., Hamauchi S., Kawakami T., Fushiki K. Lenvatinib rechallenge after failure of lenvatinib and sorafenib in metastatic thyroid cancer. Invest New Drugs 2024;42(4):361–8. DOI:10.1007/s10637-024-01449-9; Guo R., Chen X., Wang T. et al. Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer. BMC Cancer 2011;11:90. DOI:10.1186/1471-2407-11-90; Becker A., Crombag L., Heideman D.A. et al. Retreatment with erlotinib: regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment. Eur J Cancer 2011;47(17):2603–6. DOI:10.1016/j.ejca.2011.06.046; Brose M.S., Panaseykin Y., Konda B. et al. A randomized study of lenvatinib 18 mg vs 24 mg in patients with radioiodine-refractory differentiated thyroid Cancer. J Clin Endocrinol Metab 2022;107(3):776–87. DOI:10.1210/clinem/dgab731; Yu J., Liu Z., Su Y. et al. Tyrosine kinase inhibitors for radioiodine refractory differentiated thyroid cancer: a systematic review and meta-analysis. Clin Endocrinol (Oxf) 2024;100(4):379–88. DOI:10.1111/cen.15027; https://ogsh.abvpress.ru/jour/article/view/1023
-
4Academic Journal
Συγγραφείς: Francis Worden, Olivera Rajkovic-Hooley, Neil Reynolds, Gary Milligan, Jingchuan Zhang
Πηγή: Endocrine
Опухоли головы и шеи, Vol 15, Iss 2, Pp 26-33 (2025)Θεματικοί όροι: Male, Adult, радиойодрефрактерность, Phenylurea Compounds, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Antineoplastic Agents, Middle Aged, соединенные штаты америки, анализ историй болезни, United States, 3. Good health, Iodine Radioisotopes, ленватиниб, Treatment Outcome, Quinolines, Humans, Original Article, Female, Thyroid Neoplasms, дифференцированный рак щитовидной железы, RC254-282, эффективность препарата в реальной клинической практике, Retrospective Studies, Aged
Συνδεδεμένο Πλήρες ΚείμενοΣύνδεσμος πρόσβασης: https://pubmed.ncbi.nlm.nih.gov/38102498
https://doaj.org/article/13e795881b584176942973349d347b1b -
5Academic Journal
Συγγραφείς: Lori J Wirth, Cosimo Durante, Duncan J Topliss, Eric Winquist, Eyal Robenshtok, Hiroyuki Iwasaki, Markus Luster, Rossella Elisei, Sophie Leboulleux, Makoto Tahara
Πηγή: Oncologist
Опухоли головы и шеи, Vol 12, Iss 4, Pp 81-90 (2023)Θεματικοί όροι: токсичность, радиойодрефрактерность, differentiated thyroid cancer, lenvatinib, radioiodine refractory, systemic therapy, toxicity, Humans, Iodine Radioisotopes, Phenylurea Compounds, Protein Kinase Inhibitors, Adenocarcinoma, Antineoplastic Agents, Quinolines, Thyroid Neoplasms, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, 3. Good health, ленватиниб, Endocrinology, дифференцированный рак щитовидной железы, системная терапия, RC254-282
-
6Academic Journal
Συγγραφείς: M. S. Brose, Yu. Panaseykin, B. Konda, C. De la Fouchardiere, B. G.M. Hughes, A. G. Gianoukakis, Y. J. Park, I. Romanov, M. K. Krzyzanowska, S. Leboulleux, T. A. Binder, C. Dutcus, R. Xie, M. H. Taylor
Πηγή: Опухоли головы и шеи, Vol 12, Iss 1, Pp 86-98 (2022)
Θεματικοί όροι: 03 medical and health sciences, ленватиниб, 0302 clinical medicine, стартовая доза, ингибитор тирозинкиназ, радиойодрефрактерный дифференцированный рак щитовидной железы, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Σύνδεσμος πρόσβασης: https://doaj.org/article/d7a35ee1dee346c98829477eec0b69b8
-
7Academic Journal
Συγγραφείς: A. Yu. Shurinov, E. V. Borodavina, V. V. Krylov, M. A. Sigov, A. A. Rodichev, S. A. Ivanov, A. D. Kaprin, А. Ю. Шуринов, Е. В. Бородавина, В. В. Крылов, М. A. Сигов, А. А. Родичев, С. А. Иванов, А. Д. Каприн
Πηγή: Head and Neck Tumors (HNT); Том 14, № 1 (2024); 83-95 ; Опухоли головы и шеи; Том 14, № 1 (2024); 83-95 ; 2411-4634 ; 2222-1468 ; 10.17650/2222-1468-2024-14-1
Θεματικοί όροι: ответ на лечение, differentiated thyroid cancer, radioiodine therapy, radioiodine remnant ablation, radioiodine-refractory, follow-up menagments, post-therapeutic scintigraphy of the whole body, response to treatment, дифференцированный рак щитовидной железы, радиойодтерапия, радиойодаблация, радиойодрефрактерность, динамическое наблюдение, посттерапевтическая сцинтиграфия всего тела
Περιγραφή αρχείου: application/pdf
Relation: https://ogsh.abvpress.ru/jour/article/view/973/624; Чойнзонов Е.Л., Решетов И.В., Иванов С.А. и др. Проект клинических рекомендаций по диагностике и лечению дифференцированного рака щитовидной железы у взрослых пациентов. Эндокринная хирургия 2022;16(2):5—29. DOI:10.14341/serg12792; Шишкина В.В., Чеботарева Э.Д., Семичев Д.С. Лечебное применение открытых радионуклидов. Киев, 1988. С. 4—10.; Filetti S., Bidart J., Arturi F. et al. Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism. Eur J Endocrinol 1999;141(5):443-57. DOI:10.1530/eje.0.1410443; Боголюбова А.В., Абросимов А.Ю., Селиванова Л.С., Белоусов П.В. Гистологическая и молекулярно-генетическая характеристика клинически агрессивных вариантов папиллярного рака щитовидной железы. Архив патологии 2019;81(1):46—51. DOI:10.17116/patol20198101146; Tuttle R., Ahuja S., Avram A. et al. Controversies, consensus, and collaboration in the use of 131I therapy in differentiated thyroid cancer: a joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association. Thyroid 2019;29(4):461-70. DOI:10.1089/thy.2018.0597; Shaha A. Implications of prognostic factors and risk groups in the management of differentiated thyroid cancer. Laryngoscope 2004;114(3):393-402. DOI:10.1097/00005537-200403000-00001; Haugen B., Alexander E., Bible Keith C. et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2016;26(1):1-133. DOI:10.1089/thy.2015.0020; Каприн А.Д., Мардынский Ю.С. Терапевтическая радиология. М.: ГЭОТАР-Медиа, 2018.; Cooper D., Doherty G., Haugen B. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16(2):109-42. DOI:10.1089/thy.2006.16.109; Sawka A., Ibrahim-Zada I., Galacgac P. et al. Dietary iodine restriction in preparation for radioactive iodine treatment or scanning in well-differentiated thyroid cancer: a systematic review. Thyroid 2010;20(10):1129-38. DOI:10.1089/thy.2010.0055; Maxon H., Thomas S., Boehringer A. et al. Low iodine diet in I-131 ablation of thyroid remnants. Clin Nucl Med 1983;8(3):123-6. DOI:10.1097/00003072-198303000-00006; Shankar L.K., Yamamoto A.J., Alavi A., Mandel S.J. Comparison of 123I scintigraphy at 5 and 24 hours in patients with differentiated thyroid cancer. J Nucl Med 2002;43(1):72-6.; Санитарные правила и нормативы (СанПиН) 2.6.1.2368-08. «Гигиенические требования по обеспечению радиационной безопасности при проведении лучевой терапии с помощью открытых радионуклидных источников» (утв. постановлением Главного государственного санитарного врача РФ от 16.06.2008 № 36).; NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Thyroid Carcinoma. Version 2.2022.; Filetti S., Durante C., Hartl D. et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019;30(12):1856-83. DOI:10.1093/annonc/mdz400; Dewaraja Y.K., Ljungberg M., Green A.J. et al. MIRD pamphlet No. 24: Guidelines for quantitative 131I SPECT in dosimetry applications. J Nucl Med 2013;54(12):2182-8. DOI:10.2967/jnumed.113.122390; Van Nostrand D. Sialoadenitis secondary to 131I therapy for well-differentiated thyroid cancer. Oral Dis 2011;17(2):154-61. DOI:10.1111/j.1601-0825.2010.01726.x; Burns J., Morgenstern K., Cahill K. et al. Nasolacrimal duct obstruction secondary to I131 therapy. Ophthal Plast Reconstr Surg 2004;20(2):126-9. DOI:10.1097/01.iop.0000117340.41849.81; Wu J.X., Young S., Ro K. et al. Reproductive outcomes and nononcologic complications after radioactive iodine ablation for well-differentiated thyroid cancer. Thyroid 2015;25(1):133-8. DOI:10.1089/thy.2014.0343; Pacini F., Gasperi M., Fugazzola L. et al. Testicular function in patients with differentiated thyroid carcinoma treated with radioiodine. J Nucl Med 1994;35(9):1418-22.; Wichers M., Benz E., Palmedo H. et al. Testicular function after radioiodine therapy for thyroid cancer. Eur J Nucl Med 2000;27(5):503-7. DOI:10.1007/s002590050535; Handelsman D.J., Conway A.J., Donnelly P.E., Turtle J.R. Azoospermia after iodine-131 treatment for thyroid carcinoma. Br Med J 1980;281(6254):1527. DOI:10.1136/bmj.281.6254.1527; Климанов В.А. Ядерная медицина. Радионуклидная диагностика: учебное пособие для вузов. 2-е изд., испр. и доп. М.: Юрай, 2022.; Шуринов А.Ю., Бородавина Е.В. Динамический контроль после радиойодабляции при дифференцированном раке щитовидной железы - взгляд радиолога. Опухоли головы и шеи 2023;13(1):91-101. DOI:10.17650/2222-1468-2023-13-1-91-101; Haugen B.R., Alexander E.K., Bible K.C. et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016;26(1):1-133. DOI:10.1089/thy.2015.0020; https://ogsh.abvpress.ru/jour/article/view/973
-
8Academic Journal
Συγγραφείς: Smoliar, V.A., Tovkay, О.А., Palamarchuk, V.О., Khoperiya, V.G.
Πηγή: Mìžnarodnij Endokrinologìčnij Žurnal, Vol 14, Iss 8, Pp 749-755 (2018)
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY; Том 14, № 8 (2018); 749-755
Международный эндокринологический журнал-Mìžnarodnij endokrinologìčnij žurnal; Том 14, № 8 (2018); 749-755
Міжнародний ендокринологічний журнал-Mìžnarodnij endokrinologìčnij žurnal; Том 14, № 8 (2018); 749-755Θεματικοί όροι: диференційований рак щитоподібної залози, дисекція лімфатичних вузлів, огляд, differentiated thyroid cancer, lymph node dissection, review, 03 medical and health sciences, 0302 clinical medicine, дифференцированный рак щитовидной железы, диссекция лимфатических узлов, обзор, RC648-665, Diseases of the endocrine glands. Clinical endocrinology, 3. Good health
Περιγραφή αρχείου: application/pdf
-
9Academic Journal
Συγγραφείς: A. Yu. Shurinov, E. V. Borodavina, А. Ю. Шуринов, Е. В. Бородавина
Πηγή: Head and Neck Tumors (HNT); Том 13, № 1 (2023); 91-101 ; Опухоли головы и шеи; Том 13, № 1 (2023); 91-101 ; 2411-4634 ; 2222-1468 ; 10.17650/2222-1468-2023-13-1
Θεματικοί όροι: TENIS-синдром, dynamic observation, differentiated thyroid cancer, 131 I whole-body scintigraphy, 131 I single-photon emission computed tomography/X-ray computed tomography, 18 F-fluorodeoxyglucose positron emission tomography/computed tomography, TENIS syndrome, динамическое наблюдение, дифференцированный рак щитовидной железы, сцинтиграфия всего тела с 131 I, однофотонная эмиссионная компьютерная томография, совмещенная с рентгеновской компьютерной томографией, с 131 I, позитронная эмиссионная томография, совмещенная с компьютерной томографией, с 18 F-фтордезоксиглюкозой
Περιγραφή αρχείου: application/pdf
Relation: https://ogsh.abvpress.ru/jour/article/view/871/575; Filetti S., Durante C., Hartl D., Leboulleux S. et al. Berruti on behalf of the ESMO Guidelines Committee. 2019. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019;30(12):1856–83. DOI:10.1093/annonc/mdz400; Клинические рекомендации. Дифференцированный рак щитовидной железы. 2020 г. Доступно по: https://cr.minzdrav.gov.ru/schema/329_1#doc_a1.; Gulec S., Ahuja S., Avram A. et al. A joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the European Thyroid Association, the Society of Nuclear Medicine and Molecular Imaging on Current Diagnostic and Theranostic Approaches in the Management of Thyroid Cancer. Thyroid 2021;31(7):1009–19. DOI:10.1089/ thy.2020.0826; Haddad R., Bischoff L., Ball D. et al. Thyroid Carcinoma. Version 2.2022. NCCN Clinical Practice Guidelines in Oncology. J Nat Compr Canc Netw 2022;20(8):925–51. DOI:10.6004/ jnccn.2022.0040; Шуринов А.Ю., Крылов В.В., Бородавина Е.В. Радиойодаблация при раке щитовидной железы. Исторические и современные аспекты. Обзор литературы. Онкологический журнал: лучевая диагностика, лучевая терапия 2021;4(4):9–19. DOI:10.37174/2587-7593-2021-4-4-9-19; Duren M., Siperstein A., Shen W. et al. Value of stimulated serum thyroglobulin levels for detecting persistent or recurrent differentiated thyroid cancer in high- and low-risk patients. Surgery 1999;26(1):13–9. DOI:10.1067/msy.1999.98849; Pacini F., Lippi F., Formica N. et al. Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. J Nucl Med 1987;28(12):1888–91.; Pineda J., Lee T., Ain K. et al. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 1995;80(5):1488–92. DOI:10.1210/ jcem.80.5.7744991; Roelants V., De Nayer P., Bouckaert A., Beckers C. The predictive value of serum thyroglobulin in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1997;24:722–7. DOI:10.1007/ BF00879658; Pacini F., Molinaro E., Castagna M. et al. Ablation of thyroid residues with 30 mCi 131I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab 2002;87(9):4063–8. DOI:10.1210/jc.2001-011918; Kukulska A., Krajewska J., Gawkowska-Suwiriska M. et al. Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60, and 100 mCi. Thyroid Res 2010;3(1):9. DOI:10.1186/1756-6614-3-9; Toubeau M., Touzery C., Arveux P. et al. Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after 131I ablation therapy in patients with differentiated thyroid cancer. J Nucl Med 2004;45(6):988–94.; Haugen B., Alexander E., Bible K.C. et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016;26(1):1–133. DOI:10.1089/thy.2015.0020; Lamartina L., Grani G., Durante C., Filetti S. Recent advances in managing differentiated thyroid cancer. F1000Res 2018;7:86. DOI:10.12688/f1000research.12811.1; Gray J., Singh G., Uttley L., Balasubramanian S. Routine thyroglobulin, neck ultrasound and physical examination in the routine follow up of patients with differentiated thyroid cancer: where is the evidence? Endocrine 2018;62(1):26–33. DOI:10.1007/s12020-018-1720-3; Prpić M., Franceschi M., Romić M. et al. Thyroglobulin as a tumor marker in differentiated thyroid cancer – clinical considerations. Acta Clin Croat 2018;57(3):518–27. DOI:10.20471/acc.2018.57.03.16; Giovanella L., Clark P., Chiovato L. et al. Thyroglobulin measurement using highly sensitive assays in patients with differentiated thyroid cancer: a clinical position paper. Eur J Endocrinol 2014;171(2):R33–46. DOI:10.1530/EJE-14-0148; Spencer C. Clinical review: clinical utility of thyroglobulin antibody (TgAb) measurements for patients with differentiated thyroid cancers (DTC). J Clin Endocrinol Metab 2011;96(12):3615–27. DOI:10.1210/jc.2011-1740; Dekker B., Van der Horst-Schrivers A., Brouwers A. et al. Clinical irrelevance of lower titer thyroglobulin autoantibodies in patients with differentiated thyroid carcinoma. Eur Thyroid J 2022 20;11(6):e220137. DOI:10.1530/ETJ-22-0137; Brassard M., Borget I., Edet-Sanson A. et al. Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients. J Clin Endocrinol Metab 2011;96(5):1352–9. DOI:10.1210/jc.2010-2708; Durante C., Montesano T., Attard M. et al. Long-term surveillance of papillary thyroid cancer patients who do not undergo postoperative radioiodine remnant ablation: is there a role for serum thyroglobulin measurement? J Clin Endocrinol Metab 2012;97(8):2748–53. DOI:10.1210/jc.2012-1123; Angell T., Spencer C., Rubino B. et al. In search of an unstimulated thyroglobulin baseline value in low-risk papillary thyroid carcinoma patients not receiving radioactive iodine ablation. Thyroid 2014;24(7):1127–33. DOI:10.1089/thy.2013.0691; Grani G., Fumarola A. Thyroglobulin in lymph node fine-needle aspiration washout: a systematic review and meta-analysis of diagnostic accuracy. J Clin Endocrinol Metab 2014;99(6):1970–82. DOI:10.1210/jc.2014-1098; Torlontano M., Attard M., Crocetti U. et al. Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases. J Clin Endocrinol Metab 2004;89(7):3402–7. DOI:10.1210/ jc.2003-031521; Grani G., Lamartina L., Cantisani V. et al. Enterobserver agreement of various thyroid imaging reporting and data systems. Endocr Connect 2018;7(1):1–7. DOI:10.1530/EC-17-0336; Lamartina L., Grani G., Biffoni M. et al. Risk stratification of neck lesions detected sonographically during the follow-up of differentiated thyroid cancer. J Clin Endocrinol Metab 2016;101(8):3036–44. DOI:10.1210/jc.2016-1440; Leboulleux S., Girard E., Rose M. et al. Ultrasound criteria of malignancy for cervical lymph nodes in patients followed up for differentiated thyroid cancer. J Clin Endocrinol Metab 2007;92(9):3590–4. DOI:10.1210/jc.2007-0444; Leenhardt L., Erdogan M., Hegedus L. et al. 2013 European Thyroid Association guidelines for cervical ultrasound scan and ultrasound-guided techniques in the postoperative management of patients with thyroid cancer. Eur Thyroid J 2013;2(3):147–59. DOI:10.1159/000354537; Lamartina L., Deandreis D., Durante C., Filetti S. ENDOCRINE TUMOURS: imaging in the follow-up of differentiated thyroid cancer: current evidence and future perspectives for a risk-adapted approach. Eur J Endocrinol 2016;175(5):R185–202. DOI:10.1530/ EJE-16-0088; Grani G., Ramundo V., Falcone R. et al. Thyroid cancer patients with no evidence of disease: the need for repeat neck ultrasound. J Clin Endocrinol Metab 2019;104(11):4981–9. DOI:10.1210/jc.2019-00962; Castagna M., Maino F., Cipri C. et al. Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. Eur J Endocrinol 2011;165(3):441–6. DOI:10.1530/EJE-11-0466; Tuttle R., Tala H., Shah J. et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 2010;20(12):1341–9. DOI:10.1089/thy.2010.0178; Durante C., Attard M., Torlontano M. et al. Identification and optimal postsurgical follow-up of patients with very low-risk papillary thyroid microcarcinomas. J Clin Endocrinol Metab 2010;95(11):4882–8. DOI:10.1210/jc.2010-0762; Tuttle R., Tala H., Shah J. et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 2010; 20(12):1341–9. DOI:10.1089/thy.2010.0178; Jeon M., Kim W., Park W. et al. Modified dynamic risk stratification for predicting recurrence using the response to initial therapy in patients with differentiated thyroid carcinoma. Eur J Endocrinol 2014;170:23–30. DOI:10.1530/EJE-13-0524; Han J., Kim W., Yim J. et al. Long-term clinical outcome of differentiated thyroid cancer patients with undetectable stimulated thyroglobulin level one year after initial treatment. Thyroid 2012;22(8):784–90. DOI:10.1089/thy.2011.0322; Scheffel R., Zanella A., Antunes D. et al. Low recurrence rates in a cohort of differentiated thyroid carcinoma patients: a referral center experience. Thyroid 2015;25(8):883–9. DOI:10.1089/thy.2015.0077; Llamas-Olier A., Cuéllar D., Buitrago G. Intermediate-risk papillary thyroid cancer: risk factors for early recurrence in patients with excellent response to initial therapy. Thyroid 2018;28(10):1311–7. DOI:10.1089/thy.2017.0578; Ganly I., Nixon I., Wang L. et al. Survival from differentiated thyroid cancer: what has age got to do with it? Thyroid 2015;25(10):1106–14. DOI:10.1089/thy.2015.0104; Comtois R., Theriault C., Del Vecchio P. Assessment of the efficacy of iodine-131 for thyroid ablation. J Nucl Med 1993;34(11):1927–30.; Schlumberger M., Berg G., Cohen O. et al. Follow-up of low-risk patients with differentiated thyroid carcinoma. Eur J Endocrinol 2004;150(2):105–12. DOI:10.1530/eje.0.1500105; Sacks W., Fung C., Chang J. et al. The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: a systematic analysis of the peer-reviewed literature from 1966 to April 2008. Thyroid 2010;20(11):1235–45. DOI:10.1089/thy.2009.0455; Dietlein M., Eschner W., Grünwald F. et al. Procedure guidelines for radioiodine therapy of differentiated thyroid cancer. Nuklearmedizin 2016;55:77–89. DOI:10.1055/s-0037-1616478; Gastanga M., Cantara S., Pacini F. Reappraisal of the indication for radioiodine thyroid ablation in differentiated thyroid cancer patients. J Endocrinol Invest 2016;39(10):1087–94. DOI:10.1007/s40618-016-0503-z; Deandreis D., Rubino C., Tala H. et al. Comparison of empiric versus whole-body-blood clearance dosimetry-based approach to radioactive iodine treatment in patients with metastases from differentiated thyroid cancer. J Nucl Med 2017;58(5):717–22. DOI:10.2967/jnumed.116.179606; Verburg F., Schmidt M., Kreissl M. et al. Procedural guideline for Iodine-131 whole-body scintigraphy in differentiated thyroid carcinoma (version 5). Nuklearmedizin 2019;58(3):228–41. DOI:10.1055/a-0891-1839; Giovanella L., Treglia G., Sadeghi R. et al. Unstimulated highly sensitive thyroglobulin in follow-up of differentiated thyroid cancer patients: a meta-analysis. J Clin Endocrinol Metab 2014;99(2):440– 7. DOI:10.1210/jc.2013-3156; Francis G., Waguespack S., Bauer A. et al. American Thyroid Association Guidelines Task Force Management guidelines for children with thyroid nodules and differentiated thyroid cancer. Thyroid 2015;25(7):716–59. DOI:10.1089/thy.2014.0460; Li J., He Z., Bansal V., Hennessey J. Low iodine diet in differentiated thyroid cancer: a review. Clin Endocrinol (Oxf) 2016;84(1):3–12. DOI:10.1111/cen.12846; Campennì А., Barbaro D., Guzzo M. et al. Personalized management of differentiated thyroid cancer in real life – practical guidance from a multidisciplinary panel of experts. Endocrine 2020;70(2):280–91. DOI:10.1007/s12020-020-02418-x; Feine U., Lietzenmayer R., Hanke J. et al. 18FDG whole-body PET in differentiated thyroid carcinoma. Flipflop in uptake patterns of 18FDG and 131I. [In German]. Nuklearmedizin 1995;34(4):127–34.; Feine U., Lietzenmayer R., Hanke J. et al. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 1996;37(9):1468–72.; Asa S., Aksoy S., Vatankulu B. et al. The role of FDG-PET/CT in differentiated thyroid cancer patients with negative iodine-131 whole-body scan and elevated anti-Tg level. Ann Nucl Med 2014;28(10):970–9. DOI:10.1007/s12149-014-0897-7; Liu Y. The role of 18F-FDG PET/CT in the follow-up of well-differentiated thyroid cancer with negative thyroglobulin but positive and/or elevated antithyroglobulin antibody. Nucl Med Commun 2016;37(6):577–82. DOI:10.1097/MNM.0000000000000480; Ozkan E., Aras G., Kucuk N. Correlation of 18F-FDG PET/CT findings with histopathological results in differentiated thyroid cancer patients who have increased thyroglobulin or antithyroglobulin antibody levels and negative 131I whole-body scan results. Clin Nucl Med 2013;38(5):326–31. DOI:10.1097/RLU.0b013e318286827b; Liu M., Cheng L., Jin Y. et al. Predicting 131I-avidity of metastases from differentiated thyroid cancer using 18F-FDG PET/CT in postoperative patients with elevated thyroglobulin. Sci Rep 2018;8(1):4352. DOI:10.1038/s41598-018-22656-4; Silberstein E. The problem of the patient with thyroglobulin elevation but negative iodine scintigraphy: the TENIS syndrome. Semin Nucl Med 2011;41(2):113–20. DOI:10.1053/j.semnuclmed.2010.10.002; Bartel C., Magerefteh S., Avram A. et al. Snmmi procedure standard for scintigraphy for differentiated thyroid cancer. J Nucl Med Technol 2020;48(3):202–9. DOI:10.2967/jnmt.120.243626; Avram А., Giovanella L., Greenspan B. et al. SNMMI procedure standard/eanm practice guideline for nuclear medicine evaluation and therapy of differentiated thyroid cancer: abbreviated version. J Nucl Med 2022;63(6):15N–35N.; Petranović P., Kreissl M., Campenni A. et al. SNMMI/EANM practice guideline vs. ETA Consensus Statement: differences and similarities in approaching differentiated thyroid cancer management-the EANM perspective. Eur J Nucl Med Mol Imaging 2022;49(12):3959–63. DOI:10.1007/s00259-022-05935-1; Giovanella L., Treglia G., Ceriani L., Verburg F. Detectable thyroglobulin with negative imaging in differentiated thyroid cancer patients. What to do with negative anatomical imaging and radioiodine scan? Nuklearmedizin 2014;53(1):1–10. DOI:10.3413/Nukmed-0618-13-08; Van Nostrand D. Radioiodine imaging for differentiated thyroid cancer: not all radioiodine images are performed equally. Thyroid 2019;29(7):901–9.; Donohoe K., Aloff J., Avram А. et al. Appropriate use criteria for nuclear medicine in the evaluation and treatment of differentiated thyroid cancer. J Nucl Med 2020;61(3):375–96. DOI:10.2967/jnumed.119.240945; Binse I., Poeppel T., Ruhlmann M. et al. 68Ga-DOTATOC PET/CT in patients with iodine- and 18F-FDG-negative differentiated thyroid carcinoma and elevated serum thyroglobulin. J Nucl Med 2016;57(10):1512–7. DOI:10.2967/jnumed.115.171942; Vrachimis A., Stegger L., Wenning C. et al. 68Ga-DOTATATE PET/ MRI and 18F-FDG PET/CT are complementary and superior to diffusion-weighted MR imaging for radioactive-iodine-refractory differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2016;43(10):1765–72. DOI:10.1007/s00259-016-3378-5; Czepczynski R., Matysiak-Grzes M., Gryczynska M. et al. Peptide receptor radionuclide therapy of differentiated thyroid cancer: efficacy and toxicity. Arch Immunol Ther Exp (Warsz) 2015;63(2):147–54. DOI:10.1007/s00005-014-0318-6; Versari A., Sollini M., Frasoldati A. et al. Differentiated thyroid cancer: A new perspective with radiolabeled somatostatin analogues for imaging and treatment of patients. Thyroid 2014;24(4):715–26. DOI:10.1089/thy.2013.0225; Roll W., Riemann B., Schafers M. et al. 177Lu-DOTATATE therapy in radioiodine-refractory differentiated thyroid cancer: a single center experience. Clin Nucl Med 2018;43(10):e346–51. DOI:10.1097/RLU.0000000000002219; Gubbi S., Koch C., Klubo-Gwiezdzinska J. Peptide receptor radionuclide therapy in thyroid cancer. Front endocrinol (Lausanne) 2022;13:896287. DOI:10.3389/fendo.2022.896287; Ryu Y.J., Lim S.Y., Na Y.M. et al. Prostate-specific membrane antigen expression predicts recurrence of papillary thyroid carcinoma after total thyroidectomy. BMC Cancer 2022;22(1):1278. DOI:10.1186/s12885-022-10375-z; Piek M., De Vries L., Donswijk M. et al. Ploeg IMC. Retrospective analysis of PSMA PET/CT thyroid incidental uptake in adults: incidence, diagnosis, and treatment/outcome in a tertiary cancer referral center and University Medical Center. Eur J Nucl Med Mol Imaging 2022;49(7):2392–400. DOI:10.1007/s00259-022-05679-y; https://ogsh.abvpress.ru/jour/article/view/871
-
10Academic Journal
Συγγραφείς: Borodavina E.V., Shurinov A.Y., Kutukova S.I., Nedozorova E.N., Malanchuk A.V., Semenchenko Y.V., Povarkov S.M., Narovenkova K.V., Khodkevich A.V., Komoza Y.V., Kofanova K.A., Dmitriev S.P., Vasilyeva E.B., Shikhamirova S.A., Gorshenina M.N., Volodina L.N., Snezhko O.A., Stativko O.A., Xenodokhov D.V., Dzhemageldieva Y.G., Khryapa A.I., Ulimaeva D.M., Dagba E.M., Volkonsky M.V., Filippova V.M., Skorina M.O., Romanchuk O.V., Andrienko I.I., Shorin M.V., Ishchenko A.A., Dumbrava R.A., Bolieva M.B., Tsarakhova F.V., Gojieva Z.A., Dzhamirzaeva S.S., Aidaeva P.Z., Maximov M.O., Usoltseva I.S., Milyukova A.O., Toporkova O.V., Sychev V.D., Rudakov S.A., Sagdieva S.T., Klochikhin M.A., Molokova V.V., Skotnikov R.A., Yeremina E.N., Panaseikin Y.A., Tyugina Y.A., Murzina Y.I., Podvyaznikov S.O.
Συνεισφορές: The article was published with the financial support of Eisai Co., Ltd., Данная статья подготовлена при финансовой поддержке ООО «Эйсай»
Πηγή: Head and Neck Tumors; Vol 13, No 4 (2023); 73-82 ; Опухоли головы и шеи; Vol 13, No 4 (2023); 73-82 ; 2411-4634 ; 2222-1468
Θεματικοί όροι: differentiated thyroid cancer, radioiodrefract cancer, “watch and wait” approach, дифференцированный рак щитовидной железы, радиойодрефрактерный рак, подход «наблюдай и жди»
Περιγραφή αρχείου: application/pdf
Relation: https://ogsh.abvpress.ru/jour/article/view/939/614; https://ogsh.abvpress.ru/jour/article/view/939
-
11Academic Journal
Συγγραφείς: M. E. Cabanillas, S. Takahashi
Πηγή: Опухоли головы и шеи, Vol 9, Iss 4, Pp 49-61 (2020)
Θεματικοί όροι: 0301 basic medicine, Carcinoma, Hepatocellular, Drug-Related Side Effects and Adverse Reactions, Phenylurea Compounds, Liver Neoplasms, побочные эффекты, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, 3. Good health, Iodine Radioisotopes, 03 medical and health sciences, ленватиниб, 0302 clinical medicine, Quinolines, Humans, Everolimus, Thyroid Neoplasms, ингибиторы тирозинкиназы, Carcinoma, Renal Cell, Protein Kinase Inhibitors, нежелательные явления, дифференцированный рак щитовидной железы, RC254-282
Σύνδεσμος πρόσβασης: https://ogsh.abvpress.ru/jour/article/download/453/407
https://pubmed.ncbi.nlm.nih.gov/30685073
https://doaj.org/article/1174679614e242efb794a609c0ac7c22
https://www.ncbi.nlm.nih.gov/pubmed/30685073
https://mdanderson.elsevierpure.com/en/publications/managing-the-adverse-events-associated-with-lenvatinib-therapy-in
https://www.sciencedirect.com/science/article/abs/pii/S0093775418302203
https://www.sciencedirect.com/science/article/pii/S0093775418302203
https://europepmc.org/article/MED/30685073
https://pubmed.ncbi.nlm.nih.gov/30685073/
https://ogsh.abvpress.ru/jour/article/view/453
https://ogsh.abvpress.ru/jour/article/download/453/407
https://mdanderson.elsevierpure.com/en/publications/managing-the-adverse-events-associated-with-lenvatinib-therapy-in-2 -
12Academic Journal
Συγγραφείς: T. M. Geliashvili, A. V. Vazhenin, T. P. Berezovskaya, E. B. Vasilieva, N. G. Afanasieva, V. V. Krylov, P. I. Garbuzov, Т. М. Гелиашвили, А. В. Важенин, Т. П. Березовская, Е. Б. Васильева, Н. Г. Афанасьева, В. В. Крылов, П. И. Гарбузов
Πηγή: Head and Neck Tumors (HNT); Том 10, № 4 (2020); 16-24 ; Опухоли головы и шеи; Том 10, № 4 (2020); 16-24 ; 2411-4634 ; 2222-1468 ; 10.17650/2222-1468-2020-0-4
Θεματικοί όροι: предабляционный уровень тиреоглобулина, positron emission tomography, differentiated thyroid cancer, radioiodine therapy, pre-ablation thyroglobulin leve, позитронная эмиссионная томография, дифференцированный рак щитовидной железы, радиойодтерапия
Περιγραφή αρχείου: application/pdf
Relation: https://ogsh.abvpress.ru/jour/article/view/577/448; Kitahara C.M., Devesa S.S., Sosa J.A. Increases in thyroid cancer incidence and mortality-reply. JAMA 2017;318(4):390–1. DOI:10.1001/jama.2017.7910.; Haugen B.R., Alexander E.K., Bible K.C. et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016;26(1):1–133. DOI:10.1089/thy.2015.0020.; Santhanam P., Solnes L.B., Rowe S.P. Molecular imaging of advanced thyroid cancer: iodinated radiotracers and beyond. Med Oncol 2017;34(12):189. DOI:10.1007/s12032-017-1051-x.; Fatourechi V., Hay I.D., Mullan B.P. et al. Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer? Thyroid 2000;10(7):573–7. DOI:10.1089/thy.2000.10.573.; Sheikh A., Polack B., Rodriguez Y., Kuker R. Nuclear molecular and theranostic imaging for differentiated thyroid cancer. Mol Imaging Radionucl Ther 2017;26(Suppl 1):50–65. DOI:10.4274/2017.26.suppl.06.; Choudhury P.S., Guptа M. Differentiated thyroid cancer theranostics: radioiodine and beyond. Br J Radiol 2018;91(1091):20180136. DOI:10.1259/bjr.20180136.; Rosenbaum-Krumme S.J., Gorges R., Bockisch A., Binse I. 18F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy. Eur J Nucl Med Mol Imag 2012;39(9):1373–80. DOI:10.1007/s00259-012-2065-4.; Lee J.W., Lee S.M., Lee D.H., Kim Y.J. Clinical utility of 18F-FDG PET/CT concurrent with 131I therapy in intermediate-to-high-risk patients with differentiated thyroid cancer: dual-center experience with 286 patients. J Nucl Med 2013;54(8):1230–6. DOI:10.2967/jnumed.112.117119.; Gaertner F.C., Okamoto S., Shiga T. et al. FDG PET performed at thyroid remnant ablation has a higher predictive value for long-term survival of high-risk patients with well-differentiated thyroid cancer than radioiodine uptake. Clin Nucl Med 2015;40(5):378–83. DOI:10.1097/RLU.0000000000000699.; Nascimento C., Borget I., Al Ghuzlan A. et al. Postoperative fluorine-18-fluoro- deoxyglucose positron emission tomography/computed tomography: an important imaging modality in patients with aggressive histology of differentiated thyroid cancer. Thyroid 2015;25:437–44. DOI:10.1089/thy.2014.0320.; Triviño Ibáñez E.M., Muros M.A., Torres Vela E., Llamas Elvira J.M. The role of early 18F-FDG PET/CT in therapeutic management and ongoing risk stratification of high/intermediate-risk thyroid carcinoma. Endocrine 2015;51(3):490–8. DOI:10.1007/s12020-015-0708-5.; Qiu Z.-L., Wei W.-J., Shen C.-T. et al. Diagnostic performance of 18F-FDG PET/ CT in papillary thyroid carcinoma with negative 131I-WBS at first postablation, negative Tg and progressively increased TgAb level. Sci Rep 2017;7(1):2849. DOI:10.1038/s41598-017-03001-7.; Ruhlmann M., Binse I., Bockisch A., Rosenbaum-Krumme S.J. Initial [18F] FDG PET/CT in high-risk DTC patients. A three-year follow-up. Nuklearmedizin 2016;55:99–103. DOI:10.3413/Nukmed-0766-15-09.; Chang Y.W., Kim H.S., Jung S.P. et al. Pre-ablation stimulated thyroglobulin is a better predictor of recurrence in pathological N1a papillary thyroid carcinoma than the lymph node ratio. Int J Clin Oncol 2016;21:862–8. DOI:10.1007/s10147-016-0956-2.; Cho S.G., Kwon S.Y., Kim J. et al. Risk factors of malignant fluorodeoxyglucoseavid lymph node on preablation positron emission tomography in patients with papillary thyroid cancer undergoing radioiodine ablation therapy. Medicine (Baltimore) 2019;98(16):e14858. DOI:10.1097/MD.0000000000014858.; Shangguan L., Fang S., Zhang P. et al. Impact factors for the outcome of the first 131I radiotherapy in patients with papillary thyroid carcinoma after total thyroidectomy. Ann Nucl Med 2019;33:177–83. DOI:10.1007/s12149-018-01321-w.; Liu M., Cheng L., Jin Y. et al. Predicting 131I-avidity of metastases from differentiated thyroid cancer using 18F-FDG PET/CT in postoperative patients with elevated thyroglobulin. Sci Rep 2018;8(1):4352. DOI:10.1038/s41598-018-22656-4; Kwon S.Y., Kim J., Jung S.H. et al. Preablative stimulated thyroglobulin levels can predict malignant potential and therapeutic responsiveness of subcentimeter-sized, 18F-fluorodeoxyglucose-avid cervical lymph nodes in patients with papillary thyroid cancer. Clin Nucl Med 2016;41(1):e32–8. DOI:10.1097/RLU.0000000000000889.; https://ogsh.abvpress.ru/jour/article/view/577
-
13Academic Journal
Συγγραφείς: Guda, B. B., Kovalenko, A. E., Taraschenko, Yu. M.
Πηγή: Hospital Surgery. Journal named by L.Ya. Kovalchuk; No. 2 (2019); 22-27 ; Госпитальная хирургия. Журнал имени Л.А. Ковальчука; № 2 (2019); 22-27 ; Шпитальна хірургія. Журнал імені Л. Я. Ковальчука; № 2 (2019); 22-27 ; 2414-4533 ; 1681-2778 ; 10.11603/2414-4533.2019.2
Θεματικοί όροι: differentiated thyroid cancer, thyroidectomy, minimally invasive thyroidectomy, дифференцированный рак щитовидной железы, тиреоидэктомия, мини-доступ, диференційований рак щитоподібної залози, тиреоїдектомія, міні-доступ
Περιγραφή αρχείου: application/pdf
Relation: https://ojs.tdmu.edu.ua/index.php/surgery/article/view/10414/9973; https://ojs.tdmu.edu.ua/index.php/surgery/article/view/10414; https://repository.tdmu.edu.ua//handle/123456789/13323
-
14Academic Journal
Συγγραφείς: T. M. Geliashvili, A. V. Vazhenin, T. P. Berezovskaya, N. G. Afanasyeva, E. V. Vasilyeva, P. I. Garbuzov, V. V. Krylov, Т. М. Гелиашвили, А. В. Важенин, Т. П. Березовская, Н. Г. Афанасьева, Е. Б. Васильева, П. И. Гарбузов, В. В. Крылов
Πηγή: Head and Neck Tumors (HNT); Том 9, № 4 (2019); 10-16 ; Опухоли головы и шеи; Том 9, № 4 (2019); 10-16 ; 2411-4634 ; 2222-1468 ; 10.17650/2222-1468-2019-9-4
Θεματικοί όροι: сцинтиграфия всего тела, differentiated thyroid cancer, radioiodine therapy, post-therapeutic 131 I whole-body scintigraphy, позитронная эмиссионная томография, компьютерная томография, дифференцированный рак щитовидной железы, радиойодтерапия
Περιγραφή αρχείου: application/pdf
Relation: https://ogsh.abvpress.ru/jour/article/view/444/398; Hong C.M., Lee W.K., Jeong S.Y. et al. Superiority of delayed risk stratification in differentiated thyroid cancer after total thyroidectomy and radioactive iodine ablation. Nucl Med Commun 2014;35(11):1119–26. DOI:10.1097/MNM.0000000000000183.; Sampson E., Brierley J.D., Le L.W. et al. Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis. Cancer 2007;110(7):1451–6. DOI:10.1002/cncr.22956.; O’Neill C.J., Oucharek J., Learoyd D., Sidhu S.B. Standard and emerging therapies for metastatic differentiated thyroid cancer. Oncologist 2010;15(2):146–56. DOI:10.1634/theoncologist.2009-0190.; Verburg F.A., Hanscheid H., Luster M. Radioactive iodine (RAI) therapy for metastatic differentiated thyroid cancer. Best Pract Res Clin Endocrinol Metab 2017;31(3):279–90. DOI:10.1016/j.beem.2017.04.010.; Chung J.-K., Cheon G.J. Radioiodine therapy in differentiated thyroid cancer: the first targeted therapy in oncology. Endocrinol Metab (Seul) 2014;29(3):233–9. DOI:10.3803/EnM.2014.29.3.233.; Haugen B.R., Alexander E.K., Bible K.C. et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016;26(1):1–133. DOI:10.1089/thy.2015.0020.; Pacini F., Ito Y., Luster M. et al. Radioactive iodine-refractory differentiated thyroid cancer: unmet needs and future directions. Expert Rev Endocrinol Metab 2012;7(5):541–54. DOI:10.1586/eem.12.36.; Schlumberger M., Brose M., Elisei R. et al. Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol 2014;2(5):356–8. DOI:10.1016/s2213-8587(13)70215-8.; Durante C., Haddy N., Baudin E. et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006;91(8):2892–9. DOI:10.1210/jc.2005-2838.; Maxon H.R., Thomas S.R., Hertzberg V.S. et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 1983;309(16):937–41. DOI:10.1056/NEJM198310203091601.; Castro M.R., Bergert E.R., Goellner J.R. et al. Immunohistochemical analysis of sodium iodide symporter expression in metastatic differentiated thyroid cancer: correlation with radioiodine uptake. J Clin Endocrinol Metab 2001;86(11):5627–32. DOI:10.1210/jcem.86.11.8048.; Kang S.Y., Bang J.-I., Kang K.W. et al. FDG PET/CT for the early prediction of RAI therapy response in patients with metastatic differentiated thyroid carcinoma. PLoS One 2019;14(6):e0218416. DOI:10.1371/journal.pone.0218416.; Feine U., Lietzenmayer R., Hanke J.P. et al. [18 FDG whole-body PET in differentiated thyroid carcinoma. Flip-flop in uptake patterns of18 FDG and131 I (In German)]. Nuklearmedizin 1995;34(4):127–34.; Duarte P.S., Marin J.F.G., de Carvalho J.W.A. et al. Iodine/FDG “flip-flop” phenomenon inside a large metastatic thyroid cancer lesion better characterized on SPECT/CT and PET/CT studies. Clin Nucl Med 2018;43(6):436–8. DOI:10.1097/RLU.0000000000002046.; Pace L., Klain M., Salvatore B. et al. Prognostic role of18 F-FDG PET/CT in the postoperative evaluation of differentiated thyroid cancer patients. Clin Nucl Med 2015;40(2):111–5. DOI:10.1097/RLU.0000000000000621.; Min J.J., Chung J.K., Lee Y.J. et al. Relationship between expression of the sodium/iodide symporter and131 I uptake in recurrent lesions of differentiated thyroid carcinoma. Eur J Nucl Med 2001;28(5):639–45.; Chung J.K. Sodium iodide symporter: its role in nuclear medicine. J Nucl Med 2002;43(9):1188–200.; Moon S.H., Oh Y.L., Choi J.Y. et al. Comparison of18 F-fluorodeoxyglucose uptake with the expressions of glucose transporter type 1 and Na+ /I – symporter in patients with untreated papillary thyroid carcinoma. Endocr Res 2013;38(2):77–84. DOI:10.3109/07435800.2012.713426.; Kim S., Chung J.K., Min H.S. et al. Expression patterns of glucose transporter-1 gene and thyroid specific genes in human papillary thyroid carcinoma. Nucl Med Mol Imaging 2014;48(2):91–7. DOI:10.1007/s13139-013-0249-x.; Deandreis D., Al Ghuzlan A., Leboulleux S. et al. Do histological, immunohistochemical and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome? Endocr Relat Cancer 2011;18(1):159–69. DOI:10.1677/ERC-10-0233.; Rivera M., Ghossein R.A., Schoder H. et al. Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose positron emission tomography-positive thyroid carcinoma. Cancer 2008;113(1):48–56. DOI:10.1002/cncr.23515.; Liu M., Cheng L., Jin Y. et al. Predicting 131 I-avidity of metastases from differentiated thyroid cancer using 18 F-FDG PET/CT in postoperative patients with elevated thyroglobulin. Sci Rep 2018;8(1):4352. DOI:10.1038/s41598-018-22656-4.; https://ogsh.abvpress.ru/jour/article/view/444
-
15Academic Journal
Συγγραφείς: Radzishevska, Ye.B., Radzishevska, Ya.K., Kuksin, M., Savchenko, A.S., Boyko, А.N.
Πηγή: Наука и здравоохранение.
Θεματικοί όροι: қайталама анемиялар, Қалқанша безінің дифференциалды обыры, Differentiated Thyroid Cancer, радиойодтерапия, вторичные анемии, Дифференцированный рак щитовидной железы, secondary anaemia, radiotherapy, 3. Good health
-
16Academic Journal
Συγγραφείς: Nechay, O.P., Kvitka, D.M., Lishchynsky, P.O., Mazur, O.V., Palamarchuk, V.O.
Πηγή: Mìžnarodnij Endokrinologìčnij Žurnal, Vol 16, Iss 4, Pp 355-360 (2020)
Міжнародний ендокринологічний журнал-Mìžnarodnij endokrinologìčnij žurnal; Том 16, № 4 (2020); 355-360
Международный эндокринологический журнал-Mìžnarodnij endokrinologìčnij žurnal; Том 16, № 4 (2020); 355-360
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY; Том 16, № 4 (2020); 355-360Θεματικοί όροι: differentiated thyroid cancer, diagnosis, molecular genetic studies, review, дифференцированный рак щитовидной железы, диагностика, молекулярно-генетические исследования, обзор, RC648-665, Diseases of the endocrine glands. Clinical endocrinology, диференційований рак щитоподібної залози, діагностика, молекулярно-генетичні дослідження, огляд, 3. Good health
Περιγραφή αρχείου: application/pdf
-
17Academic Journal
Συγγραφείς: Radzishevska, Ye.B., Radzishevska, Ya.K., Kuksin, M., Savchenko, A.S., Boyko, А.N.
Θεματικοί όροι: қайталама анемиялар, Қалқанша безінің дифференциалды обыры, Differentiated Thyroid Cancer, радиойодтерапия, вторичные анемии, Дифференцированный рак щитовидной железы, secondary anaemia, radiotherapy, 3. Good health
-
18Academic Journal
Συγγραφείς: Palamarchuk, V. O., Tovkai, O. A., Kutz, V. V., Bodnar, M. R., Mazur, O. V., Kvitka, D. M.
Πηγή: Clinical Endocrinology and Endocrine Surgery; No. 4 (2019); 14-21 ; Clinical Endocrinology and Endocrine Surgery; № 4 (2019); 14-21 ; 2519-2582 ; 1818-1384 ; 10.30978/CEES-2019-4
Θεματικοί όροι: тиреоглобулін, радіойодотерапія, диференційований рак щитоподібної залози, ROC-аналіз, 616.441-006.6-07-08, 615.849.2, тиреоглобулин, радиойодтерапия, дифференцированный рак щитовидной железы, ROC-анализ, thyroglobulin, radioiodine therapy, differentiated thyroid gland, ROC analysis
Περιγραφή αρχείου: application/pdf
Relation: http://jcees.endocenter.kiev.ua/article/view/189286/188711; http://jcees.endocenter.kiev.ua/article/view/189286
-
19Academic Journal
Συγγραφείς: A. G. Gianoukakis, C. E. Dutcus, N. Batty, M. Guo, M. Baig
Συνεισφορές: Oxford PharmaGenesis Inc., Ньютаун, Пенсильвания, США, Inc., Woodcliff Lake, Нью-Джерси, США.
Πηγή: Head and Neck Tumors (HNT); Том 8, № 3 (2018); 53-60 ; Опухоли головы и шеи; Том 8, № 3 (2018); 53-60 ; 2411-4634 ; 2222-1468 ; 10.17650/2222-1468-2018-8-3
Θεματικοί όροι: исследование SELECT, radioiodine-refractory differentiated thyroid carcinoma, duration of response, SELECT, радиойодрефрактерный дифференцированный рак щитовидной железы, длительность ответа
Περιγραφή αρχείου: application/pdf
Relation: https://ogsh.abvpress.ru/jour/article/view/361/343; Brose M. S., Nutting C. M., Jarzab B. et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014;384(9940):319–28. DOI:10.1016/S0140-6736(14)60421-9. PMID: 24768112.; Busaidy N. L., Cabanillas M. E. Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease. J Thyroid Res 2012;2012:618985.DOI:10.1155/2012/618985. PMID: 22530159.; Cooper D. S., Doherty G. M., Haugen B. R. et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19(11):1167–214. DOI:10.1089/thy.2009.0110. PMID: 19860577.; Dieci M. V., Arnedos M., Andre F., Soria J. C. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discov 2013;3(3):264–79. DOI:10.1158/2159-8290.CD-12-0362. PMID: 23418312.; Durante C., Haddy N., Baudin E. et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006;91(8):2892–9. DOI:10.1210/jc.2005-2838. PMID: 16684830.; Haddad R. I., Schlumberger M., Wirth L. J. et al. Incidence and timing of common adverse events in Lenvatinib treated patients from the SELECT trial and their association with survival outcomes. Endocrine 2017;56(1):121–8. DOI:10.1007/s12020‑017‑1233‑5. PMID: 28155175.; Laursen R., Wehland M., Kopp S. et al. Effects and role of multikinase inhibitors in thyroid cancer. Curr Pharm Des 2016;22(39):5915–26. DOI:10.2174/1381612822666160614084943. PMID: 27306093.; Matsui J., Funahashi Y., Uenaka T. et al. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 2008;14(17):5459–65. DOI:10.1158/1078-0432.CCR-07-5270. PMID: 18765537.; Matsui J., Yamamoto Y., Funahashi Y. et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer 2008;122(3):664–71. DOI:10.1002/ijc.23131. PMID: 17943726.; Okamoto K., Kodama K., Takase K. et al. Antitumor activities of the targeted multityrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett 2013;340(1):97–103. DOI:10.1016/j.canlet. 2013.07.007. PMID: 23856031.; Pacini F., Ito Y., Luster M. et al. Radioactive iodine-refractory differentiated thyroid cancer: unmet needs and future directions. Exp Rev Endocrinol Metab 2012;7:541–54. DOI:10.1586/eem.12.36.; Pitoia F., Jerkovich F. Selective use of sorafenib in the treatment of thyroid cancer. Drug Des Devel Ther 2016;10: 1119–31. DOI:10.2147/DDDT.S82972. PMID: 27042004.; Schlumberger M., Tahara M., Wirth L. J. et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015;372(7):621–30. DOI:10.1056/NEJMoa1406470. PMID: 25671254.; St Bernard R., Zheng L., Liu W. et al. Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. Endocrinology 2005;146(3):1145–53. DOI:10.1210/en.2004-1134. PMID: 15564323.; Tohyama O., Matsui J., Kodama K. et al. Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res 2014;2014:638747. DOI:10.1155/2014/638747. PMID: 25295214.; Worden F. Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer. Ther Adv Med Oncol 2014;6(6):267–79. DOI:10.1177/1758834014548188. PMID: 25364392.; Xing M., Haugen B. R., Schlumberger M. Progress in molecularbased management of differentiated thyroid cancer. Lancet 2013;381(9871):1058–69. DOI:10.1016/S0140-6736(13)60109-9. PMID: 23668556.; Yamamoto Y., Matsui J., Matsushima T. et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell 2014;6:18. DOI:10.1186/2045-824X-6-18. PMID: 25197551.; https://ogsh.abvpress.ru/jour/article/view/361
-
20Academic Journal
Συγγραφείς: T. M. Geliashvili, A. V. Vazhenin, N. G. Afanas’eva, Т. М. Гелиашвили, А. В. Важенин, Н. Г. Афанасьева
Πηγή: Head and Neck Tumors (HNT); Том 7, № 1 (2017); 12-21 ; Опухоли головы и шеи; Том 7, № 1 (2017); 12-21 ; 2411-4634 ; 2222-1468 ; 10.17650/2222-1468-2017-7-1
Θεματικοί όροι: тиреоглобулин, differentiated thyroid cancer, 131I whole body scintigraphy, radioiodine ablation, thyroglobulin, совмещенная с компьютерной томографией, дифференцированный рак щитовидной железы, сцинтиграфия всего тела с радиоактивным йодом-131, радиойодабляция
Περιγραφή αρχείου: application/pdf
Relation: https://ogsh.abvpress.ru/jour/article/view/229/250; Чиссов В.И., Дарьялова С.Л. Онкология. М.: ГЭОТАР-Медиа, 2007. [Chissov V.I., Daryalova S.L. Oncology. Moscow: GEOTAR-Media, 2007. (In Russ.)].; Злокачественные новообразования в России в 2013 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2015. [Malignant neoplasms in Russia in 2013 (morbidity and mortality). Eds. A.D. Kaprin, V.V. Starinsky, G.V. Petrova.Moscow, 2015. (In Russ.)].; Sherman S.I. Thyroid carcinoma. Lancet 2003;361(9356):501–11. DOI:10.1016/S0140- 6736(03)12488-9. PMID: 12583960; Sipos J.A., Mazzaferri E.L. Thyroid Cancer Epidemiology and Prognostic Variables. Clin Oncol (R Coll Radiol) 2010;22(6):395–404. DOI:10.1016/j.clon.2010.05.004. PMID: 20627675; Eustatia-Rutten C.F., Corssmit E.P., Biermasz N.R. et al. Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab 2006;91(1):313–9. DOI:10.1210/jc.2005-1322. PMID: 16263822; Davies L., Welch H.G. Increasing incidence of thyroid cancer in the United States, 1973– 2002. JAMA 2006;295(18):2164–7. DOI:10.1001/jama.295.18.2164. PMID: 16684987; Schonberger J., Ruschoff J., Grimm D. et al. Glucose transporter 1 gene expression is related to thyroid neoplasms with an unfavorable prognosis: an immunohistochemical study. Thyroid 2002;12(9):747–54. DOI:10.1089/105072502760339307. PMID: 12481939; Grabellus F., Nagarajah J., Bockisch A. et al. Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma. Clin Nucl Med 2012;37(2):121–7. DOI:10.1097/RLU.0b013e3182393599. PMID: 22228332; Bongiovanni M., Paone G., Ceriani L. et al. Cellular and molecular basis for thyroid cancer imaging in nuclear medicine. Clin Transl Im 2013;1(3):149–61. DOI:10.1007/s40336-013-0025-z.; Заплатников К., Менцель К., Диль М. и др. Позитронно-эмиссионная томография с 18F-фтордезоксиглюкозой в ракурсе современной диагностики, диспансерного наблюдения и лечения дифференцированного рака щитовидной железы. Проблемы эндокринологии 2004;(1–2):46–50. [Zaplatnikov K., Mentsel’ K., Dil’ M. et al. Positron emission tomography with 18F-fluorodepxyglucose in current diagnostics, out-patient observation, and treatment of thyroid cancer. Problems of Endocrinology 2004; (1–2):46–50. (In Russ.)].; Wadsak W., Mitterhauser M. Basics and principles of radiopharmaceuticals for PET/CT. Eur J Radiol 2010;73(3):461–9. DOI:10.1016/j.ejrad.2009.12.022. PMID: 20181453; Joensuu H., Ahonen A. Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose. J Nucl Med 1987;28(5):910–4. PMID: 3572549.; Feine U., Lietzenmayer R., Hanke J.P. et al. Fluorine-18-FDG and iodine-131- iodide uptake in thyroid cancer. J Nucl Med 1996;37(9):1468–72. PMID: 8790195; Seo Y.L., Yoon D.Y., Baek S. et al. Detection of neck recurrence in patients with differentiated thyroid cancer: comparison of ultrasound, contrastenhanced CT and (18)F- FDG PET/CT using surgical pathology as a reference standard: (ultrasound vs. CT vs. (18) F- FDG PET/CT in recurrent thyroid cancer). Eur Radiol 2012;22(10):2246–54. DOI:10.1007/s00330-012-2470-x. PMID: 22562091; Seo J.H., Lee S.W., Ahn B.C., Lee J. Recurrence detection in differentiated thyroid cancer patients with elevated serum level of antithyroglobulin antibody: special emphasis on using (18)F-FDG PET/CT. Clin Endocrinol (Oxf) 2010;72(4):558–63. DOI:10.1111/j.1365- 2265.2009.03693.x. PMID: 19744107; Hall N.C., Kloos R.T. PET imaging in differentiated thyroid cancer: where does it fit and how do we use it? Arq Bras Endocrinol Metabol 2007;51(5):793–805. DOI:10.1590/S0004- 27302007000500017. PMID: 17891243; O’Neill C.J., Oucharek J., Learoyd D., Sidhu S.B. Standard and emerging therapies for metastatic differentiated thyroid cancer. Oncologist 2010;15(2):146–56. DOI:10.1634/theoncologist.2009-0190. PMID: 20142332; Durante C., Haddy N., Baudin E. et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006;91(8):2892–9. DOI:10.1210/jc.2005-2838. PMID: 16684830; Валдина Е.А. Заболевания щитовидной железы: Руководство. СПб.: Питер, 2006. [Valdina E.A. Thyroid disorders. Guidelines. Saint-Petersburg: Piter, 2006. (In Russ.)].; Schlumberger M.J. Diagnostic follow-up of well-differentiated thyroid carcinoma: Historical perspective and current status. J Endocrinol Invest 1999;22(11 suppl): 3–7. PMID: 10726999; Casara D., Rubello D., Saladini G. et al. Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate analysis of prognostic variables. J Nucl Med 1993;34(10):1626–31. PMID: 8410272; Schlumberger M.J., Arcangioli O., Piekarski J.D. et al. Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays. J Nucl Med 1988;29(11):1790–4. PMID: 3183748; King A.D. Imaging for staging and management of thyroid cancer. Cancer Imaging 2008;8:57–69. DOI:10.1102/1470-7330.2008.0007. PMID: 18390389; Kucuk O.N., Gultekin S.S., Aras G., Ibis E. Radioiodine whole-body scans, thyroglobulin levels, 99mTc-MIBI scans and computed tomography: results in patients with lung metastases from differentiated thyroid cancer. Nucl Med Commun 2006;27(3):261–6. PMID: 16479246; Dietlein M., Scheidhauer K., Voth E. et al. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1997;24(11):1342–8. PMID: 9371865; Salvatori M., Biondi B., Rufini V. Imaging in endocrinology: 2-[18F]-fluoro-2- deoxy-D- glucose positron emission tomography/computed tomography in differentiated thyroid carcinoma: clinical indications and controversies in diagnosis and follow-up. Eur J Endocrinol 2015;173(3):R115–30. DOI:10.1530/EJE-15-0066. PMID: 25947140; Leboulleux S., Schroeder P.R., Busaidy N.L. et al. Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer. J Clin Endocrinol Metab 2009;94(4):1310–6. DOI:10.1210/jc.2008-1747. PMID: 19158200; Padovani R.P., Robenshtok E., Brokhin M., Tuttle R.M. Even without additional therapy, serum thyroglobulin concentrations often decline for years after total thyroidectomy and radioactive remnant ablation in patients with differentiated thyroid cancer. Thyroid 2012;22(8):778–83. DOI:10.1089/thy.2011.0522. PMID: 22780333; Tuttle R.M., Tala H., Shah J. et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 2010;20(12):1341–9. DOI:10.1089/thy.2010.0178.; Cooper D.S., Doherty G.M., Haugen B.R. et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19(11):1167–214. DOI:10.1089/thy.2009.0110. PMID: 19860577; Treglia G., Bertagna F., Piccardo A., Giovanella L. 131-I- whole-body scan or 18-FDG- PET/CT for patients with elevated thyroglobulin and negative ultrasound? Clin Translat Im 2013;1(3):175–83. DOI:10.1007/s40336-013-0024-0.; Leboulleux S., El Bez I., Borget I. et al. Postradioiodine treatment whole body scan in the era of fluorodesoxyglucose positron emission tomography for differentiated thyroid carcinoma with elevated serum thyroglobulin levels. Thyroid 2012;22(8):832–8. DOI:10.1089/thy.2012.0081.; Dong M.J., Liu Z.F., Zhao K. et al. Value of 18F-FDG-PET/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan. Meta-analysis. Nucl Med Commun 2009;30(8):639–50. DOI:10.1097/MNM.0b013e32832dcfa7. PMID: 19512954; Kim W.G., Ryu J.S., Kim E.Y. et al. Empiric high-dose 131-Iodine therapy lacks efficacy for treated papillary thyroid cancer patients with detectable serum thyroglobulin, but negative cervical sonography and 18-F-Fluorodeoxyglucose positron emission tomography scan. J Clin Endocrinol Metab 2010;95(3):1169–73. DOI:10.1210/jc.2009-1567.; Giovanella L. Positron emission tomography/computed tomography in patients treated for differentiated thyroid carcinomas. Exp Rev Endocrinol Metab 2012;7(1):35–43. DOI:10.1586/eem.11.83.; Pacak K., Eisenhofer G., Goldstein D.S. Functional imaging of endocrine tumors: role of positron emission tomography. Endocr Rev 2004;25(4):568–80. DOI:10.1210/er.2003-0032. PMID: 15294882; Robbins R.J., Wan Q., Grewal R.K. et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2- deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 2006;91(2):498–505. DOI:10.1210/jc.2005-1534. PMID: 16303836; Deandreis D., Al Ghuzlan A., Leboulleux S. et al. Do histological, immunohistochemical and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome? Endocr Relat Cancer 2011;18(1):159–69. DOI:10.1677/ERC-10-0233.; Wang W., Larson S.M., Fazzari M. et al. Prognostic value of [18F] fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocr Metab 2000;85(3):1107–13. DOI:10.1210/jcem.85.3.6458. PMID: 10720047; Pryma D.A., Schoder H., Gonen M. Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients. J Nucl Med 2006;47(8):1260–6. PMID: 16883003; Rosenbaum-Krumme S.J., Gorges R., Bockisch A., Binse I. 18F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy. Eur J Nucl Med Mol Imaging 2012;39(9):1373–80. DOI:10.1007/s00259-012-2065-4. PMID: 22718304; Gaertner F.C., Okamoto S., Shiga T. et al. FDG PET performed at thyroid remnant ablation has a higher predictive value for long-term survival of high-risk patients with well- differentiated thyroid cancer than radioiodine uptake. Clin Nucl Med 2015;40(5):378–83. DOI:10.1097/RLU.0000000000000699. PMID: 25608175; Sisson J.C., Ackermann R.J., Meyer M.A., Wahl R.L. Uptake of 18-fluoro-2-deoxy- D- glucose by thyroid cancer: implications for diagnosis and therapy. J Clin Endocrinol Metab 1993;77(4):1090–4. DOI:10.1210/jcem.77.4.8408458. PMID: 8408458; van Tol K.M., Jager P.L., Piers D.A. et al. Better yield of (18)fluorodeoxyglucosepositron emission tomography in patients with metastatic differentiated thyroid carcinoma during thyrotropin stimulation. Thyroid 2002;12(5):381–7. DOI:10.1089/105072502760043459. PMID: 12097198; Grunwald F., Biersack H.J. FDG PET in thyroid cancer: thyroxine or not? J Nucl Med 2000;41(12):1996–8. PMID: 11138684; Marcus C., Whitworth P.W., Surasi D.S. et al. PET/CT in the management of thyroid cancers. AJR Am J Roentgenol 2014;202(6):1316–29. DOI:10.2214/AJR.13.11673.; Vural G.U., Akkas B.E., Ercakmak N. et al. Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data. Clin Nucl Med 2012;37:953–9. DOI:10.1097/RLU.0b013e31825b2057. PMID: 22899202; Zoller M., Kohlfuerst S., Igerc I. et al. Combined PET/CT in the follow-up of differentiated thyroid carcinoma: what is the impact of each modality? Eur J Nucl Med Mol Imaging 2007;34(4):487–95. DOI:10.1007/s00259-006-0276-2. PMID: 17103166; Bertagna F., Bosio G., Biasiotto G. et al. F-18 FDGPET/CT evaluation of patients with differentiated thyroid cancer with negative I-131 total body scan and high thyroglobulin level. Clin Nucl Med 2009; 34:756–61. DOI:10.1097/RLU.0b013e3181b7d95c. PMID: 19851169; Schluter B., Bohuslavizki K.H., Beyer W. et al. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J Nucl Med 2001;42(1):71–6. PMID: 11197983; Shammas A., Degirmenci B., Mountz J.M. et al. 18F-FDG PET/CT in patients with suspected recurrent or metastatic welldifferentiated thyroid cancer. J Nucl Med 2007;48(2):221–6. PMID: 17268018; Bertagna F., Biasiotto G., Orlando E. et al. Role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients affected by differentiated thyroid carcinoma, high thyroglobulin level, and negative 131I scan: review of the literature. Jpn J Radiol 2010;28(9):629–36. DOI:10.1007/s11604-010-0488-z.; Zimmer L.A., McCook B., Meltzer C. et al. Combined positron emission tomography/computed tomography imaging of recurrent thyroid cancer. Otolaryngol Head Neck Surg 2003;128(2):178–84. DOI:10.1067/mhn.2003.74. PMID: 12601311; Giovanella L., Trimboli P., Verburg F.A. et al. Thyroglobulin levels and thyroglobulin doubling time independently predict a positive 18F-FDG PET/CT scan in patients with biochemical recurrence of differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 2013;40(6):874–80. DOI:10.1007/s00259-013-2370-6. PMID: 2346330; Nanni C., Rubello D., Fanti S. et al. Role of 18F-FDG-PET and PET/CT imaging in thyroid cancer. Biomed Pharmacother 2006;60(8):409–13. DOI:10.1016/j.biopha.2006.07.008. PMID: 16891093; Palmedo H., Bucerius J., Joe A. et al. Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med 2006;47(4):616–24. PMID: 16595495; https://ogsh.abvpress.ru/jour/article/view/229